Compare AERT & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERT | NSRX |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | Singapore | Israel |
| Employees | 1400 | 7 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 25.8M |
| IPO Year | N/A | N/A |
| Metric | AERT | NSRX |
|---|---|---|
| Price | $0.65 | $3.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 270.4K | 107.6K |
| Earning Date | 02-09-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.26 | $1.98 |
| 52 Week High | $1.52 | $9.99 |
| Indicator | AERT | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.41 | 53.67 |
| Support Level | $0.63 | $2.16 |
| Resistance Level | $0.73 | $4.49 |
| Average True Range (ATR) | 0.05 | 0.50 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 90.31 | 40.97 |
Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.